Skip to Content
Morningstar

Strong Moats for Undervalued Big Pharma Firms

Strong Moats for Undervalued Big Pharma Firms

In our analysis of the Big Pharma companies, we continue to see the industry as well positioned with strong economic moats. While our analysis reaffirms most of our moat ratings, we are increasing Bayer's moat to wide from narrow. Bayer's divestiture of its material science group combined with a strong drug business and a well-positioned crop science business (bolstered by the Monsanto acquisition) led us to upgrade its moat rating to wide.

Key to all the moats for Big Pharma companies is the increasing focus on innovation in areas of unmet medical need, enabling strong pricing power to offset the increasing negotiating power from the pharmacy benefit managers in the U.S. and restrictive pricing in developed markets outside of the U.S. While drugs carry patent protection, allowing firms to charge near monopolistic prices, a drug's true pricing power is determined by several factors, including its benefit to patients and its uniqueness.

As segments within Big Pharma firms, animal health and consumer healthcare both carry strong moats, augmenting the moat strength derived in the human-branded drug segment. Overall, the moat analysis guides our discounted cash flow valuations, which support our view that Pfizer, Bayer, GlaxoSmithKline, and Sanofi are undervalued.

MORN DODFX VINIX VWILX TSVA EGO WU Brightstart429plan MRO VZ MOAT T NKE CMCSA GOOG

More in Stocks

About the Author

Damien Conover

Sector Director
More from Author

Damien Conover, CFA, is the director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar’s investment philosophy by working closely with the firm’s sector strategists and directors.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

Damien Conover, CFA, is the director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar’s investment philosophy by working closely with the firm’s sector strategists and directors.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

Sponsor Center